Protein biomarkers such as S100A2, OAS2 and/or IFNβ RNA expression in breast tumors may prove to be useful guides in predicting the response of IFN-positive patients to anti-interferon therapeutics. The gene discussed is IFNA1; the disease is breast neoplasm.